PDRadiopharma

Executive Summary

PDRadiopharma is a Japanese radiopharmaceutical company specializing in targeted radionuclide therapies and diagnostics for oncology. The company's lead program, 177Lu-PSMA-I&T, is a next-generation radioligand therapy designed to deliver beta-emitting radiation directly to prostate cancer cells expressing PSMA, thereby minimizing off-target toxicity. Currently in Phase 3 clinical development, this program targets a significant unmet need in metastatic castration-resistant prostate cancer (mCRPC), a large and growing market. PDRadiopharma leverages its deep expertise in radioisotope chemistry and precision medicine to develop differentiated candidates that could offer improved efficacy and safety over existing therapies, such as Novartis' Pluvicto. The company is poised for a pivotal data readout from its Phase 3 trial in the coming quarters, which could serve as a major catalyst for regulatory filings in Japan and potentially the US and EU. With a lean operational structure and a clear focus on prostate cancer, PDRadiopharma represents an attractive opportunity in the radiopharmaceutical space. The company's technology platform also has potential for expansion into other PSMA-expressing tumors, providing additional pipeline optionality. Given the strong preclinical and early clinical data, as well as the increasing adoption of radioligand therapies, we view PDRadiopharma as a high-conviction investment candidate.

Upcoming Catalysts (preview)

• H2 2026Phase 3 Top-Line Data for 177Lu-PSMA-I&T in mCRPC70% success
• 2027Regulatory Submission (NDA/MAA) for 177Lu-PSMA-I&T in Japan65% success
• TBDPotential Licensing or Partnership Deal for Ex-Japan Rights50% success